Breaking down frailty: Assessing vulnerability in acute myeloid leukemia

Area of Science:

• Hematology
• Geriatric Medicine
• Oncology

Background:

• Acute Myeloid Leukemia (AML) predominantly affects older adults.
• Treatment decisions in elderly AML patients are complicated by frailty, impacting suitability for intensive chemotherapy.
• Current guidelines lack consensus on optimal treatment selection for less fit older AML patients.

Purpose of the Study:

• To review the literature on frailty assessments in older adults with AML.
• To evaluate the predictive ability of frailty measures and Comprehensive Geriatric Assessment (CGA) for treatment outcomes.
• To identify potential biomarkers and patient-reported outcomes for enhanced geriatric assessment.

Main Methods:

• Systematic review of 37 studies assessing frailty and composite indices in AML.
• Analysis of data on Comprehensive Geriatric Assessment (CGA), Geriatric 8 (G8) risk score, and hematopoietic cell transplant comorbidity index (HCT-CI).
• Evaluation of studies on biomarkers (albumin, C-reactive protein) and patient-reported outcomes.

Main Results:

• Frailty assessments and CGA measures show heterogeneous results in predicting treatment outcomes for AML patients.
• CGA, G8 risk score, and HCT-CI are associated with prognosis in older AML patients.
• Biomarkers and patient-reported outcomes may augment information from geriatric assessments.

Conclusions:

• Validated geriatric assessment tools are needed for better treatment selection in older AML patients.
• Further validation of CGA, G8, and HCT-CI in larger clinical trials is recommended.
• Integrating biomarkers and patient-reported outcomes can improve the comprehensive assessment of elderly AML patients.